Chemically Coupled Transporters for Low-Hydrophobic Bioactive Drugs into the Central Nervous System

Abstract

The present disclosure provides compounds comprising modified tetracycline derivatives covalently coupled with a less hydrophobic biologically active molecule useful for treating neurodegenerative diseases through a linker defined by the general formula XZX, specifically, the modified tetracycline derivative is a chemically modified doxycycline derivative, and the less hydrophobic biologically active molecule useful for treating neurodegenerative diseases is dopamine. The present disclosure also provides processes for preparing such compounds, as well as methods for treating neurodegenerative diseases comprising administering the compounds.

Description

[Technical Field]

[0001] FIELD OF THE INVENTION The present invention generally relates to chemically coupled compounds useful as drug carriers. More specifically, the present invention refers to such compounds for the treatment of neurodegenerative diseases. Specifically, the present invention refers to compounds comprising modified tetracycline derivatives covalently coupled via a linker to low-hydrophobic biologically active molecules useful for treating neurodegenerative diseases. Even more specifically, the drug carrier compounds disclosed herein have been proven useful and effective in in vitro experimental models of neurodegenerative diseases, particularly Parkinson's disease (PD). [Background technology]

[0002] Background of the Invention Neurodegenerative diseases are a heterogeneous group of disorders characterized by the progressive loss of selectively vulnerable populations of neurons in the central or peripheral nervous system. While age is the primary risk factor for developing neurodegenerative diseases, the increasing lifespan of the human population poses significant challenges to healthcare systems throughout developed countries. Virtually every systematic study conducted solely on Alzheimer's disease estimates that 7.7 million people are affected in the US alone, a number that is expected to rise to 13.5 million by 2050. Additionally, actual expenditures on dementia care in the UK are roughly equivalent to the costs of cancer, heart disease, and stroke combined. This highlights the urgent need for effective neuroprotective treatments to avoid healthcare system collapse in the near future.

[0003] Although various neurodegenerative disorders exhibit differences in clinical symptoms, they share many commonalities at the subcellular level, including amyloid protein aggregation (Stefani M, Dobson CM. Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med. 2003;81(11):678-99; Murphy RM. Peptide aggregation in neurodegenerative disease. Annu Rev Biomed Eng. 2002;4:155-74; Duda JE, Lee VM, Trojanowski JQ. Neuropathology of synuclein aggregates. J Neurosci Res. 2000;61(2):121-7), neuroinflammation (A, Gallea JI, Sarroukh R, Celej MS, Ruysschaert JM, Raussens V. Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease. Biochem J. 2015;471(3):323-33. doi: 10.1042 / BJ20150617), oxidative stress (Pukass K, Richter-Landsberg C. Oxidative stress promotes uptake, accumulation, and oligomerization of extracellular alpha-synuclein in oligodendrocytes. J Mol Neurosci. 2014;52(3):339-52. doi: 10.1007 / s12031-013-0154-x; Bieschke J, Zhang Q, Powers ET, Lerner RA, Kelly JW.Oxidative metabolites accelerate Alzheimer's amyloidogenesis by a two-step mechanism, eliminating the requirement for nucleation. Biochemistry. 2005;44(13):4977-83), and mitochondrial dysfunction (Nakamura K. alpha-Synuclein and mitochondria: partners in crime? Neurotherapeutics. 2013;10(3):391-9. doi: 10.1007 / s13311-013-0182-9; Hsu LJ, Sagara Y, Arroyo A, Rockenstein E, Sisk A, Mallory M, et al. alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am J Pathol. 2000;157(2):401-10. Epub 2000 / 08 / 10. doi: 10.1016 / s0002-9440(10)64553-1), and lysosomal dysregulation (Wallings RL, Humble SW, Ward ME, Wade-Martins R. Lysosomal Dysfunction at the Center of Parkinson's Disease and Frontotemporal Dementia / Amyotrophic Lateral Sclerosis. Trends Neurosci. 2019 Dec;42(12):899-912. doi: 10.1016 / j.tins.2019.10.002. Epub 2019 Nov 5. PMID: 31704179; PMCID: PMC6931156).

[0004] An ideal treatment would directly target the underlying disease pathogenesis as a primary method of altering the increasingly progressive clinical course of these diseases. It is widely accepted that the aggregation of specific proteins not only shares common molecular features but also likely triggers subsequent neuroinflammation, oxidative stress, lysosomal dysregulation, and mitochondrial dysfunction. Furthermore, all of these events appear to be linked in a positive feedback loop of neurotoxicity. Therefore, inhibiting abnormal protein aggregation should be a primary therapeutic target for amyloid-related diseases. Unfortunately, despite significant investment in research and drug discovery, all attempts to date have failed.

[0005] Although promising compounds have demonstrated the ability to stop or reverse protein aggregation in vitro or in animal models, unfortunately, most of these have failed in clinical trials. Moreover, most drugs that have reached phase 3 and are currently listed as neuroprotective in clinical trial registry databases primarily aim to regulate neurotransmitter release or metabolism instead of inhibiting the abnormal protein aggregation process (https: / / clinicaltrials.gov / ). Therefore, available approaches are more palliative than cure.

[0006] Therapeutic approaches to treat neurodegenerative diseases are often limited due to the protective properties of the blood-brain barrier (BBB), which prevents drug targeting to neurons. The BBB acts as an organic barrier between the circulating blood and the central nervous system (CNS), controlling homeostasis, the movement of molecules and ions, regulating influx and efflux transport, and acting as a protective cover to prevent harmful substances from penetrating into the brain. This complex barrier also controls and limits the systemic delivery of therapeutic agents to the CNS. The highly permeable BBB constitutes the greatest barrier to the delivery of drugs to treat brain disorders via the blood circulation.

[0007] The following are sometimes referred to as belonging to the group of neurodegenerative diseases: Alzheimer's disease (AD) and other dementias, Parkinson's disease (PD) and PD-related disorders, prion diseases, motor neuron diseases (MND), Huntington's disease (HD), spinocerebellar ataxias (SCAs), and spinal muscular atrophy (SMA).

[0008] Of those mentioned above, PD is the second most common neurodegenerative disorder, affecting 7-10 million people worldwide, and is characterized by motor symptoms and progressive loss of midbrain dopaminergic neurons (Collaborators GPsD. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):939-53. Epub 2018 / 10 / 01. doi: 10.1016 / S1474-4422(18)30295-3; Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain. 2017;140(7):1959-76. doi: 10.1093 / brain / awx118). Available pharmacological interventions for PD, such as levodopa and dopamine agonists, can reverse motor symptoms. However, these treatments lose efficacy over time and cause adverse side effects (Picconi B, Hernandez LF, Obeso JA, Calabresi P. Motor complications in Parkinson's disease: Striatal molecular and electrophysiological mechanisms of dyskinesias. Mov Disord. 2018;33(6):867-76. Epub 2017 / 12 / 08. doi: 10.1002 / mds.27261). In this context, there is a critical need to develop disease-modifying therapies to prevent or slow disease progression.

[0009] Although the molecular basis of neurodegeneration in PD remains controversial, the central role of α-synuclein (AS) amyloid aggregation in the initiation and dissemination of the pathology appears clear (Spillantinimg, Schmidtml, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839-40. Epub 1997 / 08 / 28. doi: 10.1038 / 42166; Araki K, Yagi N, Aoyama K, Choong CJ, Hayakawa H, Fujimura H, et al. Parkinson's disease is a type of amyloidosis featuring accumulation of amyloid fibrils of α-synuclein. Proc Natl Acad Sci U S A. 2019;116(36):17963-9. Epub 2019 / 08 / 21. doi: 10.1073 / pnas.1906124116). Oligomeric AS species are involved in calcium influx-associated membrane permeability changes (Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci. 2007;27(34):9220-32. doi: 10.1523 / JNEUROSCI.2617-07.2007), mitochondrial damage (Hsu LJ et al.), and lysosomal leakage (Nishino K, Hsu FF, Turk J, Cromie MJ, Wosten MM, Groisman EA).Identification of the lipopolysaccharide modifications controlled by the Salmonella PmrA / PmrB system mediating resistance to Fe(III) and Al(III). Mol Microbiol. 2006;61(3):645-54.), microtubule disruption (Alim MA, Ma QL, Takeda K, Aizawa T, Matsubara M, Nakamura M, et al. Demonstration of a role for alpha-synuclein as a functional microtubule-associated protein. J Alzheimers Dis. 2004;6(4):435-42; discussion 43-9. Epub 2004 / 09 / 04) and interference with axonal transport (Scott DA, Tabarean I, Tang Y, Cartier A, Masliah E, Roy S. A pathologic cascade leading to synaptic dysfunction in alpha-synuclein-induced neurodegeneration. J Neurosci. 2010;30(24):8083-95. Epub 2010 / 06 / 18. doi: 10.1523 / JNEUROSCI.1091-10.2010), whereas fibrillar seeds have been shown to exert toxic effects by various mechanisms, mainly by triggering inflammatory processes (Dos-Santos-Pereira M, Acuna L, Hamadat S, Rocca J, Gonzalez-Lizarraga F, Chehin R, et al. Microglial glutamate release evoked by α-synuclein aggregates is prevented by dopamine. Glia.2018;66(11):2353-65), but also catalyze their own proliferation (Bousset L, Pieri L, Ruiz-Arlandis G, Gath J, Jensen PH, Habenstein B, et al. Structural and functional characterization of two alpha-synuclein strains. Nat Commun. 2013;4:2575. doi: 10.1038 / ncomms3575), destabilize proteostasis networks (Morimoto RI, Driessen AJ, Hegde RS, Langer T. The life of proteins: the good, the mostly good and the ugly. Nat Struct Mol Biol. 2011;18(1):1-4. doi: 10.1038 / nsmb0111-1), and affect the integrity of cytosolic organelles (Flavin WP, Bousset L, Green ZC, Chu Y, Skarpathiotis S, Chaney MJ, et al. Endocytic vesicle rupture is a conserved mechanism of cellular invasion by amyloid proteins. Acta Neuropathol. 2017;134(4):629-53. Epub 2017 / 05 / 19. doi: 10.1007 / s00401-017-1722-x) also induces neurotoxicity. Considering that oxidative stress and pro-inflammatory cytokines also promote toxic aggregation of AS (Pukass K et al.), it is suggested that all these processes converge in a vicious cycle leading to neuronal death and subsequent spread of toxic species to neighboring healthy neurons (Gonzalez-Lizarraga F, Socias SB, Avila CL, Torres-Bugeau CM, Barbosa LR, Binolfi A, et al.).Repurposing doxycycline for synucleinopathies: remodeling of alpha-synuclein oligomers toward non-toxic parallel beta-sheet structured species. Sci Rep. 2017;7:41755. Epub 2017 / 02 / 06. doi: 10.1038 / srep41755). Therefore, to effectively correct the neurodegenerative process in PD, an ideal drug would be able to disrupt AS aggregation, stop the generation of toxic species, disassemble preformed toxic aggregates, and inhibit neuroinflammatory processes. In addition, such multitargeted compounds would also possess the ability to cross the BBB, an often essential obstacle in the development of drugs targeting the central nervous system. While administration of dopamine itself can compensate for the lack of this neurotransmitter, this molecule is too polar to cross the BBB. For this reason, since 1960, the most effective and widespread dopamine replacement therapy has been the delivery of its precursor, levodopa (L-Dopa or L-3,4-dihydroxyphenylalanine) (LeWitt PA. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. Mov Disord. 2015;30(1):64-72. Epub 2014 / 12 / 03. doi: 10.1002 / mds.26082). This amino acid can only cross the BBB slightly using the large amino acid transporter LAT-1, and once in the CNS, it is decarboxylated to dopamine. It is important to note that dopamine does not have any transporters reported to date and is too polar a compound to be soluble in lipids and diffuse across the BBB.

[0010] In 1975, peripheral decarboxylase inhibitors such as carbidopa or benserazide began to be added to L-Dopa preparations, reducing the dose of L-Dopa required to reach the CNS (Rinne UK, Birket-Smith E, Dupont E, Hansen E, Hyyppae M, Marttila R, et al. Levodopa alone and in combination with a peripheral decarboxylase inhibitor benserazide (Madopar) in the treatment of Parkinson's disease: A controlled clinical trial. J Neurol. 1975;211(1):1-9. doi: 10.1007 / BF00312459). These preparations were able to control important side effects such as nausea and vomiting. However, sustained use of L-Dopa in combination with carbidopa has resulted in new side effects, including movement disorders, depression, orthostatic hypotension, drowsiness, psychosis, and increased risk-taking behavior (Hinz M, Stein A, Cole T. Parkinson's disease: carbidopa, nausea, and dyskinesia. Clin Pharmacol. 2014;6:189-94. Epub 2014 / 12 / 09. doi: 10.2147 / CPAA.S72234). To date, no other modes of administration are available approved to alleviate dopamine deficiency in the nigrostriatal pathway of the CNS.

[0011] Delivery of therapeutic agents to the CNS can be divided into the following categories: 1- Unstructured system: The traditional way to deliver dopamine to the CNS is through preparations containing levodopa + carbidopa or benserazide. However, there are some side effects resulting from the continuous use of L-Dopa + carbidopa. Research into its etiology and adverse effects has demonstrated that carbidopa is the drug responsible for these side effects, as it irreversibly binds with and inactivates vitamin B6 throughout the body. It interferes with the functions of more than 300 enzymes and proteins, resulting in profound effects (Hinz M et al.). In addition, changes in thinking, including the appearance of hallucinations and delusions, are associated with the release of dopamine in the mesolimbic or mesocortical system (Rinne UK et al.).

[0012] Dopamine agonists (DAs) are an effective alternative to levodopa, primarily for younger patients, and are associated with a lower incidence of motor complications after 5 years. They are useful both as monotherapy in the early stages of the disease and in combination with levodopa in patients with advanced PD. Ergot derivatives were the first available DAs, but their use is currently limited due to the risk of cardiac valvular fibrosis.

[0013] Today, non-ergot DAs are the predominant choice. They can be administered orally (pramipexole and ropinirole), transdermally (rotigotine), or subcutaneously (apomorphine). Recently, oral sustained-release presentations have been introduced to the market, allowing for once-daily administration of the drug. However, even the newer DAs are associated with serious side effects (Reichmann H, Bilsing A, Ehret R, Greulich W, Schulz JB, Schwartz A, et al. Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease. J Neurol. 2006;253 Suppl 4:IV36-8. doi: 10.1007 / s00415-006-4009-z).

[0014] 2- Nanostructured systems: Nanoparticles of various compositions and structures are being investigated to transport drugs to the CNS. Generally, these particles are colloidal solids varying in size between 2 and 100 nm. None of these systems has yet reached the registration or commercial phase, among which the following can be mentioned: - dendrimer Dendrimers are dendritic three-dimensional polymers of polymeric species from polyamide (PAMAM), polypropyl-1-amine (DAB-dendr-NH2), polyether, polyester, polyalkane, polyphenylene, polyphenylacetylene, etc. Drugs can be encapsulated within dendrimers or covalently attached to their surface. Dendrimers penetrate the BBB through receptor-mediated endocytosis. Although drug encapsulation in dendrimers is a very promising strategy, there has been no systematic evaluation of dendrimer toxicokinetics in terms of their adsorption, distribution, metabolism, and excretion to address safety concerns regarding long-term clinical use.

[0015] To the best of our knowledge, there has been no literature disclosure to date regarding the encapsulation of dopamine or other neuroprotective molecules capable of inhibiting or halting cell death in dendrimers (Zhu Y, Liu C, Pang Z. Dendrimer-Based Drug Delivery Systems for Brain Targeting. Biomolecules. 2019;9(12). Epub 2019 / 11 / 27. doi: 10.3390 / biom9120790). Dendrimers have extremely low encapsulation efficiency and are not known to accumulate in specific regions, such as the nigrostriatal pathway.

[0016] - quantum dots These nanoparticles are fluorescent semiconductor nanoparticles that cross the BBB via transferrin receptor-mediated endocytosis. They consist of a metallic core and an organic cover. Their brightness, photostability, tunable size, and narrow emission spectrum make these nanosystems a groundbreaking technology. Various applications in the CNS, including sensitive and selective dopamine detection, have been described (Zhao D, Song H, Hao L, Liu X, Zhang L, Lv Y. Luminescent ZnO quantum dots for sensitive and selective detection of dopamine. Talanta. 2013;107:133-9. Epub 2013 / 01 / 11. doi: 10.1016 / j.talanta.2013.01.006). However, to the inventors' knowledge, the dopamine carrier function of these nanoparticles has not been reported to date. Furthermore, they exhibit inherent toxicity upon long-term treatment, and their biocompatibility has not been thoroughly investigated. Their current use is primarily focused on diagnostics.

[0017] - LiposomesLiposomes are a type of nanoparticle, typically formed by a lipid bilayer, with a hydrophilic core and a drug encapsulated within. Liposomes can cross the BBB through receptor-mediated transcytosis. Once inside the CNS, their surrounding membrane ruptures, releasing their contents. Liposomes have a limited half-life, which can be increased when their surface is coated with polyethylene glycol (PEG). The lipid bilayer helps prevent hydrolytic and oxidative degradation of the encapsulated drug.

[0018] Liposomes have been used to encapsulate apomorphine (a dopamine agonist), successfully improving drug distribution within the CNS. One group also recently investigated a liposome-based brain delivery system to target dopamine, reducing the effective dopamine dose compared with standard levodopa administration in mice (Kahana et al. Liposome-based targeting of dopamine to the brain: a novel approach for the treatment of Parkinson's disease. Mol Psychiatry. 2020 May 5. doi: 10.1038 / s41380-020-0742-4).

[0019] However, disadvantages of liposomes include poor stability, low encapsulation efficiency, rapid clearance by the reticuloendothelial system, interaction with or adsorption to cells, and high production costs.

[0020] - Micelle are colloidal particles ranging in size from 5 to 100 nm and composed of two parts: a hydrophobic interior and a hydrophilic exterior. Penetration of micelles through the BBB is achieved by receptor-mediated transcytosis. However, they are not very stable and are extremely susceptible to oxidative processes, limiting their efficiency in transporting substances into the CNS.

[0021] To date, there has been no research activity regarding the encapsulation of dopamine or other neuroprotective substances in micelles.

[0022] - carbon nanotubes Carbon nanotubes are composed of an allotropic form of carbon, consisting of one or several sheets of graphene wrapped around themselves and arranged in concentric circles, forming cylinders 1–50 nm in size and possessing unique electrical, mechanical, and thermal properties. Carbon nanotubes are inserted into the BBB, enabling drug release. Penetration of carbon nanotubes through the BBB is primarily achieved by receptor-mediated endocytosis, although other mechanisms, such as diffusion and phagocytosis, are also possible. While these nanostructures are commercially available, they are heavily contaminated with metal catalysts and amorphous carbon, which can lead to toxicity (due to inflammation), granuloma formation, biocompatibility issues, and endanger both human health and the environment.

[0023] To the best of the inventors' knowledge, there has been no such research activity to date regarding the encapsulation of dopamine or other neuroprotective substances in carbon nanotubes.

[0024] - polymer nanoparticleshave a wide range of sizes, between 1 and 1000 nm. Drugs can be attached to these nanoparticles by adsorption or covalent bonding, which keeps them bound to their surface. They are primarily characterized by their good stability. Their penetration into the BBB occurs through receptor-mediated endocytosis. Esteves et al. demonstrated that administration of these nanoparticles with retinoic acid produces a neuroprotective effect on dopaminergic neurons (Esteves M, Cristovaio AC, Saraiva T, Rocha SM, Baltazar G, Ferreira L, et al. Retinoic acid-loaded polymeric nanoparticles induce neuroprotection in a mouse model for Parkinson's disease. Front Aging Neurosci. 2015;7:20. Epub 2015 / 03 / 06. doi: 10.3389 / fnagi.2015.00020). One advantage of using nanoparticles of this type is that their chemistry is well known and there is a great deal of information regarding their toxicity.

[0025] To date, there have been no published studies on the encapsulation of dopamine or dopamine agonists in polymeric nanoparticles.

[0026] - solid lipid nanoparticlesNanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. Eur J Pharm Biopharm. 2012;80(2):306-14. Epub 2011 / 11 / 09. doi: 10.1016 / j.ejpb.2011.10.015). This intranasally administered formulation showed improvement in stiffness in a murine experimental PD model.

[0027] On the other hand, Tsai et al. formulated the dopamine receptor agonist (DA), apomorphine, into solid lipid nanoparticles and successfully increased its oral bioavailability and regional brain distribution in animal models (Tsai MJ, Huang YB, Wu PC, Fu YS, Kao YR, Fang JY, et al. Oral apomorphine delivery from solid lipid nanoparticles with different monostearate emulsifiers: pharmacokinetic and behavioral evaluations. J Pharm Sci. 2011;100(2):547-57. Epub 2010 / 08 / 27. doi: 10.1002 / jps.22285). Kondrasheva et al. designed a new carrier for L-DOPA consisting of poly(lactic-co-glycolic) PLGA and solid lipid nanoparticles, which, when administered intranasally, provides long-lasting recovery of motor function and improves drug efficacy (IG Kondrasheva, PE Gambaryan, ES Severin, AA Guseva, AA Kamensky. The application of L-DOPA-containing polymeric nanoparticles provides motor function recovery in a 6-OHDA-induced Parkinson's disease model. Journal of the Neurological Sciences. 2013, Volume 333, Supplement 1, Page e97. https: / / doi.org / 10.1016 / j.jns.2013.07.608).

[0028] Recently, studies on the encapsulation of dopamine in solid lipid nanoparticles have been published (Ortega et al. Lipid nanoparticles for the transport of drugs like dopamine through the blood-brain barrier. Beilstein Archives. 2020, 202079. https: / / doi.org / 10.3762 / bxiv.2020.79.v1; Tapeinos et al. Advances in the design of solid lipid nanoparticles and nanostructured lipid carriers for targeting brain diseases. J Control Release. 2017 October 28; 264: 306-332. doi:10.1016 / j.jconrel.2017.08.033). Disadvantages of this system include a high tendency for the vesicles to gelatinize and low drug loading efficiency. Furthermore, the availability of pure lipids and the degree of storage required for the preparation make it impractical to scale up this system to ensure it provides durable, long-term treatment.

[0029] There remains a need to develop a stable, inexpensive, and reliable delivery method for the transfer of hydrophilic drugs across the BBB to their intended targets in the CNS. Summary of the Invention

[0030] SUMMARY OF THE INVENTION According to a first aspect, the present invention provides novel compounds comprising modified tetracycline derivatives covalently coupled through a linker to a less hydrophobic biologically active molecule useful for treating neurodegenerative diseases. A second aspect of the present invention is to provide a pharmaceutical composition comprising a compound of the present invention and one or more pharmaceutically acceptable excipients.

[0031] A third aspect of the present invention provides a method for treating a neurodegenerative disease, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention. A fourth aspect of the present invention provides the use of a compound according to the present invention for the manufacture of a medicament for the treatment of a neurodegenerative disease. A fifth aspect of the present invention is to provide a process for preparing a compound according to the present invention. [Brief explanation of the drawings]

[0032] Brief description of the drawings The following figures form part of the present specification and are included to further illustrate certain aspects of the present invention. [Figure 1] FIG. 1. A representative schematic diagram of one of the compounds of the present invention, indicating the biological properties and XlogP values ​​for each of its components individually and in the coupled structure. [Figure 2] Figure 2. Effect of Pegasus (D9) on AS amyloid aggregation. Fluorescence emission intensity of 25 μM Thioflavin T in solutions containing 70 μM AS alone or with 10 μM and 50 μM D9, incubated at 37 °C, 600 rpm for 0 h and 120 h. A solution containing 70 μM AS and 50 μM doxycycline (DOX) was included as an internal control.

[0033] [Figure 3] Figure 3. MTT assay showing the effect of Pegasus (D9) on cytotoxicity in neuroblastoma SH-SY5Y cells. [Figure 4] Figure 4. MTT assay showing the effect of Pegasus (D9) on cytotoxicity in the microglial Bv2 cell line. [Figure 5] Figure 5. CellRox assay to determine the effect of Pegasus (D9) on intracellular reactive oxygen species induced by α-synuclein fibrils (ASf) in SH-SY5Y cells.

[0034] [Figure 6] Figure 6. Pro-inflammatory cytokine IL-1β assay. The effect of Pegasus (D9) on the release of IL-1β was studied in vitro in microglial cells stimulated with LPS. [Figure 7] Figure 7. Apoptosis assay in HEK293T cytochrome C-tGFP cell line. Confocal microscopy images of cytochrome C-tGFP after 24 h incubation with 200 μM Pegasus (D9) in the HEK293 / cytochrome C-tGFP cell line. [Figure 8] Figure 8. Effect of Pegasus (D9) on lysosomal activity in SH-SY5Y cells. Confocal microscopy images showing the localization and number of lysosomes after 24 h treatment with 200 μM Pegasus (D9).

[0035] [Figure 9] Figure 9. Activation of D1 dopamine receptors by Pegasus (D9). Dose-response curves in the HEK_cAMPNmd_DRD1 cell line. Cells were treated with fresh dopamine (diamonds), test dopamine (circles), Pegasus (D9) (squares), or D5 (triangles) for 24 hours. Data points represent the mean ± SD for each condition in a single experiment performed in triplicate. [Figure 10] Figure 10. Activation of D2 dopamine receptors by Pegasus (D9). Dose-response curve in the U2OS_cAMPNmd_DRD2 cell line. Cells were treated for 24 hours with fresh dopamine (diamonds), test dopamine (circles), Pegasus (D9) (squares), or D5 (triangles). Data points represent the mean ± SD for each condition in one experiment performed in triplicate. DETAILED DESCRIPTION OF THE INVENTION

[0036] Detailed Description of the Invention The present invention refers to new compounds based on structural modifications performed on tetracycline derivatives that are covalently coupled via a linker to low hydrophobic biologically active molecules useful for treating neurodegenerative diseases.

[0037] The compounds disclosed herein are useful as carriers or transporters for biologically active substances into the central nervous system. The inventors have discovered that the drug carrier compounds can cross the BBB and, as such, are useful in the treatment of neurodegenerative diseases such as Parkinson's disease (PD).

[0038] Proof of concept (POC) for the coupling system disclosed herein was performed using dopamine as the molecule to be transported. However, as anyone skilled in the art will appreciate, the present invention may be applied to any bioactive molecule with low hydrophobicity that is useful for treating neurodegenerative diseases. As previously mentioned herein, dopamine needs to be introduced into the CNS in neurodegenerative pathological conditions such as PD, but its polarity limits its access to the brain. After applying the chemical coupling procedure described herein, the resulting transporter molecule substantially increased the XlogP of free dopamine, reaching an appropriate value for permeation across the BBB. The transporter maintains its binding affinity for AS aggregates and may be targeted to the nigrostriatal region, characteristic of doxycycline, which may result in in vivo bioaccumulation in areas affected by neurodegenerative processes where these aggregates are found.

[0039] A representative schematic of the compounds of the present invention is shown in Figure 1, which indicates the biological properties and XlogP values ​​for each of its components individually and in the coupled structure. The chemically coupled transporters disclosed herein represent a new concept of site-directed drug carriers that can simultaneously exert both replacement and neuroprotective therapeutic effects.

[0040] In this sense, the present invention provides new alternatives for the treatment of neurodegenerative diseases, in particular PD, with novel compounds that address the shortcomings of currently available treatments for the mentioned clinical conditions.

[0041] When designing the synthetic scheme for the production of the compounds of the present invention, the inventors considered modifications of tetracycline, including blocking unwanted effects such as its antibiotic activity, and the addition of a functionalizable linker that easily couples the molecule to be transported. The design of the conjugated compounds of the present invention allows the two molecules to be joined by a linker that preserves their correct chemical structure.

[0042] Accordingly, it is an object of the present invention to provide new compounds comprising modified tetracycline derivatives covalently coupled through a linker to less hydrophobic biologically active molecules useful for treating neurodegenerative diseases.

[0043] Within the scope of the present invention, the term "modified tetracycline derivatives" refers to chemical compounds structurally related to tetracycline and having the formula (I): [ka] During the ceremony R1 is selected from H, CH2NHR, CH2NRR, and COR; R2 is selected from H, OH, and OCOR; R3 is selected from H and Cl; R4 is selected from H and OH; and each R is independently selected from H, alkyl, benzyl, aryl, and allyl; It is expressed as:

[0044] In a preferred embodiment of the present invention, the tetracycline derivative is a chemically modified doxycycline derivative. By "chemically modified doxycycline derivative," this description refers to compounds that are structurally related to doxycycline, an antibiotic known in the art.

[0045] Most preferably, the tetracycline derivative is a compound designated by the inventors as D5 or DOXI-5, wherein R1 is H, R2 is OH, R3 is H, and R4 is H, and has the following formula: [ka] As defined by

[0046] Within the scope of the present invention, the term "linker" refers to a small moiety that has the property of linking two structures to be coupled, in which it acts as a bifunctional connecting element.

[0047] The linkers contained within the compounds of the invention are defined by the general formula XZX. In specific embodiments of the invention, the linker is: X(-CH2-) n X, where each X is independently selected from CO and CH2, and n ranges from 0 to 16; XCH2CH2SSCH2CH2X, where each X is independently selected from OCO and HNCO; [ka] wherein X is CO; and [ka] wherein X is CO and R is an amino acid substituent. is selected from the group consisting of:

[0048] In a preferred embodiment, the linker has the formula X(—CH—) nX, where n ranges from 0 to 3. In a particularly preferred embodiment, the linker is defined by the formula X(—CH—) n X, where X is CO and n is 2.

[0049] Within the scope of the present invention, the term "low-hydrophobic biologically active molecules useful for treating neurodegenerative diseases" refers to hydrophilic chemical compounds that, when administered to a subject, exhibit biological activity at the CNS level, and are known to function as drugs for treating neurodegenerative diseases. The low hydrophobicity of such compounds hinders their passage through the BBB, preventing them from reaching their intended targets in the CNS unless they are chemically modified or an appropriate carrier system is found.

[0050] Low hydrophobic bioactive molecules useful for treating neurodegenerative diseases may be selected from a variety of drugs such as neuroprotectors, antibiotics, antifungals, antineoplastics, and anti-inflammatory drugs, among others. In a particularly preferred embodiment, the low hydrophobic bioactive molecule useful in treating neurodegenerative diseases is dopamine.

[0051] In a most preferred embodiment, the compounds of the present invention comprise dopamine as a less hydrophobic bioactive molecule useful for treating neurodegenerative diseases, compound D5 as a tetracycline derivative, and a compound of formula X(—CH—) n In such embodiments, the compound of the invention comprises a compound that the inventors have named Pegasus, which has the following formula: [ka] is defined by

[0052] The compound is also referred to as D9, and the terms "Pegasus" and "D9" are therefore used interchangeably throughout this description.

[0053] Other advantages of the compound Pegasus of the present invention are mentioned below: - It does not transport precursors, but directly transports bioactive substances. - They do not use amino acid transporters because they have the physicochemical characteristics necessary to cross the BBB. - it does not need to be administered in combination with a priori decarboxylase inhibitor, avoiding any possible side effects associated therewith. - Appears to retain the neuroprotective effects reported for doxycycline, as observed in in vitro experiments.

[0054] In an embodiment of the invention, the compounds according to the invention are intended for use in the treatment of neurodegenerative diseases.

[0055] Preferably, the neurodegenerative disease to be treated is a synucleinopathy. The term "synucleinopathy" should be understood to refer to a neurodegenerative disease characterized by the formation of toxic aggregates of AS in the CNS. Examples of synucleinopathy that may be treated by the compounds of the present invention are PD, dementia with Lewy bodies (DLB), multiple system atrophy (MSA), neuroaxonal dystrophy, and Alzheimer's disease with amygdala restricted Lewy bodies (AD / ALB). In a particularly preferred embodiment, the compounds according to the present invention are intended for use in the treatment of PD.

[0056] The compounds of the present invention are additionally intended for use in the treatment of other neurodegenerative diseases such as standard Alzheimer's disease (AD), Huntington's disease, amyotrophic lateral sclerosis, brain tumors, brain infectious diseases, among others.

[0057] The compounds of the present invention are intended to be administered to a subject in need thereof by incorporating them into a suitable pharmaceutical composition. Accordingly, it is another aspect of the present invention to provide a pharmaceutical composition comprising a compound of the present invention and one or more pharmaceutically acceptable excipients such that the compound can be readily administered to a subject.

[0058] The pharmaceutical compositions of the present invention may take several forms known to those skilled in the art. For example, the pharmaceutical compositions may be in a solid oral form, such as a tablet or capsule, or in a liquid form, such as a solution that can be administered orally or parenterally, among other things. Pharmaceutically acceptable excipients may be selected by those skilled in the art depending on, among other considerations, the dosage form selected for the pharmaceutical composition, the low hydrophobic biologically active molecule useful for treating neurodegenerative diseases to be administered, and the particular neurodegenerative disease to be treated.

[0059] As mentioned above, the compounds according to the present invention are intended for use in the treatment of neurodegenerative diseases.Accordingly, another aspect of the present invention is to provide a method for treating neurodegenerative diseases, said method comprising administering a therapeutically effective amount of the compounds of the present invention to a subject in need thereof.The neurodegenerative disease to be treated may be a synucleinopathy, preferably selected from the group consisting of PD, DLB, MSA, neuroaxonal dystrophy, and AD / ALB.Alternatively, the neurodegenerative disease to be treated may be selected from the group consisting of standard Alzheimer's disease (AD), Huntington's disease, amyotrophic lateral sclerosis, brain tumors, and infectious diseases of the brain.

[0060] One skilled in the art would be able to establish a therapeutically effective amount to administer to a subject in terms of the disease to be treated and the low hydrophobic biologically active molecule useful for treating neurodegenerative diseases to be administered.

[0061] In a particularly preferred embodiment, this aspect of the invention relates to a method for treating PD, said method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the invention.

[0062] Another aspect of the present invention is to provide a compound according to the present invention for use in the manufacture of a medicament for the treatment of a neurodegenerative disease. The neurodegenerative disease to be treated may be a synucleinopathy, preferably selected from the group consisting of PD, DLB, MSA, neuroaxonal dystrophy, and AD / ALB. Alternatively, the neurodegenerative disease to be treated may be selected from the group consisting of standard Alzheimer's disease (AD), Huntington's disease, amyotrophic lateral sclerosis, brain tumors, and infectious diseases of the brain.

[0063] One skilled in the art would be able to carry out this aspect of the invention by using the compounds of the invention to manufacture a medicament using techniques known in the art. In a particularly preferred embodiment, this aspect of the invention relates to the use of a compound according to the invention for the manufacture of a medicament for the treatment of PD.

[0064] Another aspect of the present invention is to provide a method for preparing the compound Pegasus according to the present invention, the method comprising the steps of: i) Removal of the dimethylamino function at C-4 of doxycycline. ii) Introduction of an amino function at C-9 of the deaminated product. iii) Selective protection of the phenolic hydroxyl group of dopamine (and derivatives) as benzyl ethers. iv) Introduction of a linker at the amino function of the previous product by reaction with succinic anhydride, which gives the corresponding amide-acid. v) Coupling of the acid group of the amide-acid with the amino group of doxycycline via a mixed anhydride to provide the doxycycline-dopamine conjugate, which upon deprotection of the benzyl group gives the desired compound (Pegasus).

[0065] As evidenced by the examples contained within this patent application, the methods described above surprisingly lead to the intended compounds, while other methods that were attempted were not successful in leading to said compounds.

[0066] We designed a synthetic scheme to perform suitable chemical modifications to the doxycycline molecule by eliminating its antibiotic activity, allowing it to be used for long-term treatment without creating selective pressure on the microbiota and / or the environment. In addition, it is necessary to add a linker in a region of the molecule that does not interfere with its ability to bind to aggregated species of AS. Based on our previous knowledge of the structure-function relationships of tetracyclines (Socias SB, Gonzalez-Lizarraga F, Avila CL, Vera C, Acuna L, Sepulveda-Diaz JE, et al. Exploiting the therapeutic potential of ready-to-use drugs: Repurposing antibiotics against amyloid aggregation in neurodegenerative diseases. Prog Neurobiol. 2018;162:17-36. Epub 2017 / 12 / 16. doi: 10.1016 / j.pneurobio.2017.12.002), a linker was positioned at C9, which served as a bridge covalently attaching to the dopamine molecule at the opposite end. Chemical analysis detailed below demonstrates that the structure of both molecules was maintained throughout the modification / conjugation procedure.

[0067] It is also important to emphasize that the synthetic strategy used by the inventors allows the maintenance of important biological properties of the molecule, and the resulting XlogP (partition coefficient (P), which indicates the concentration ratio of a compound at equilibrium in a mixture of two immiscible solvents) suggests that the molecule has the necessary hydrophobicity to cross the BBB.

[0068] As will be shown in the examples of the present invention, the chemically coupled transporters disclosed herein also prove to be non-toxic molecules to dopaminergic cell culture models and retain beneficial properties for protecting against neurological pathologies, such as antioxidant, anti-aggregatory, and anti-inflammatory activity.

[0069] The compounds of the present invention are useful in the treatment of PD and exhibit the following advantages: a) As a therapeutic strategy in PD and other synucleinopathies, the compounds of the present invention will have at least two targets: 1) the process of neuronal death through their neuroprotective activity derived from the tetracycline portion of the molecule, and 2) the bioaccumulation of dopamine in the nigrostriatal system, activating dopaminergic receptors, thereby serving to alleviate dopamine deficiency and interfere with disease progression. b) It improves the efficiency (as evidenced by a suitable LogP) of delivery of therapeutic compounds to the CNS (e.g., chemotherapeutic, antibiotic, antiviral, or antioxidant molecules where administration by other means is not feasible) in neurological pathological conditions. Indeed, the treatment of disorders such as HIV, dementia, epilepsy, neurogenic pain, meningitis, and brain cancer largely depends on the ability to reach higher concentrations of drugs in the brain.

[0070] Although the side effects of the compounds of the present invention still need to be studied in clinical trials, future formulations of the molecule will not require the presence of carbidopa, as the present invention does not use the precursor L-dopa or amino acid transport systems to arrive at SNC.

[0071] example The present invention is further illustrated by the following examples, which are not intended to limit its scope, but instead should be understood as merely illustrative embodiments for better taking into practice the present invention.

[0072] Example 1 - Organic synthesis of compounds of the present invention The design of synthetic schemes for the production of compounds of the present invention is described in detail below. We prepared conjugated chemical entities by attaching the two molecules using a linker. Thus, the synthesis involved suitable chemical modifications to a doxycycline molecule linked to a dopamine derivative through a spacer or linker positioned within a region that would not interfere with the binding ability of tetracycline to aggregated species of AS. As demonstrated by chemical analysis, the structures of both coupled main molecules were maintained throughout the procedure.

[0073] 1. Synthesis of the key intermediate 9-amino-4-dedimethylaminodoxycycline D5 The synthesis of D5 followed previously described procedures, with suitable modifications (International Application published as WO 2003057169; C. Berens et al. ChemBioChem 2006, 7, 1320-1324; T. C. Barden et al. J. Med. Chem. 1994, 37, 3205-3211).

[0074] The procedure employed entailed the preparation of doxycycline free form (D1) from commercially available doxycycline hydrochloride (or doxycycline hyclate). This was successfully achieved by precipitation of D1 from an aqueous solution of the salt upon addition of NaOH solution. The next step was the removal of the C-4 dimethylamino group of D1 (the numbering of the backbone C atoms is shown in Scheme I below). To this end, treatment of D1 with excess methyl iodide in THF afforded the trimethylammonium salt D2. This compound D2 was reacted with Zn(0) in acetic acid to afford the deaminated derivative D3.

[0075] Scheme I [ka]

[0076] To introduce a highly reactive functionality (amino group) into the tetracyclic core, nitration of D3 was carried out with potassium nitrate and sulfuric acid to produce the nitro derivative D4. In this process, the previously described isolation and purification protocol for D4 was modified using successive precipitations to obtain D4 in good purity. Hydrogenolysis of the nitro group of D4 then afforded the derivative 9-amino-4-dedimethylaminodoxycycline D5. The amino functionality at C-9 is essential for introducing a linker to enable conjugation of this molecule with dopamine. The nitration and hydrogenolysis steps are shown in Scheme II below.

[0077] Scheme II [ka]

[0078] 2. Introduction of a spacer (linker) into D5 or dopamine and formation of a conjugate of both units To obtain a covalent bond between D5 and dopamine, we introduced a bifunctional linking element (referred to herein as a spacer or linker) between these two molecules. 2-Chloroacetyl chloride was initially used as a linking agent. As shown in Scheme III below, reaction of this compound with D5 gave intermediate 6. Substitution of the chlorine atom by attack of the amino group of dopamine led to the doxycycline-dopamine conjugate. However, intramolecular attack of the phenolic OH at C-10 led to the cyclic compound 8.

[0079] Unfortunately, all attempts at coupling between 6 and dopamine under various reaction conditions were unsuccessful.

[0080] Scheme III [ka]

[0081] To verify whether this poor result was due to steric effects caused by the proximity of the Cl-containing reactive center to the doxycycline nucleus, longer-chain halogenated derivatives were introduced. To this end, the reaction of D5 with 5-bromovaleric acid was carried out using DCC as a coupling agent. As expected, the amide derivative D8 was obtained, as shown in Scheme IV below. This derivative D8 was characterized by NMR and MS spectroscopy. However, the next step (replacement of Br with dopamine) also did not produce satisfactory results.

[0082] Scheme IV [ka]

[0083] The synthetic strategy was then modified to involve the reaction of D5 with succinic anhydride to give the expected product (D9), see Scheme V below. Various condensing agents (DCC, EDCI, HOBt) were used for amide formation between D9 and dopamine, but no coupling product formation was observed under several conditions tested.

[0084] Scheme V [ka]

[0085] On the other hand, a modification to the reaction sequence was proposed by adding a succinic anhydride linker to dopamine. This procedure, in which the anhydride was opened by the amino group of dopamine, led to D10 (see Scheme VI below). Unfortunately, condensation of the carboxylic acid of D10 with the amino of D5 in the presence of the various condensing agents employed did not produce the expected compound.

[0086] Scheme VI [ka]

[0087] All attempts at coupling reactions between D5 and dopamine were unsuccessful; this could be attributed to the polyfunctionalization of these precursors, which could lead to unwanted interactions with other functional groups present in the molecule or to unselective reactions. For this reason, we decided to modify the synthetic strategy and attempt the reaction with an O-benzylated derivative of dopamine, which was prepared via a multistep procedure described below.

[0088] 3. Protection of the phenolic hydroxyl of dopamine (and derivatives) as benzyl ethers The phenolic hydroxyl groups of dopamine are nucleophiles that can compete with the amino group in the reaction. To inactivate these phenolic hydroxyl groups, they were protected as benzyl ethers. This protection would have the added advantage of reducing the polarity of dopamine and increasing its solubility in organic solvents in which D5 is insoluble (thus facilitating purification). In addition, protection would also prevent the formation of strong hydrogen-bonding interactions with the functionality of D5. The benzyl ethers undergo hydrogenolysis in the presence of a catalyst (Pd / C) to regenerate the original hydroxyl groups. To obtain the benzyl ethers, the procedure described by B. Xu et al. (J. Am. Chem. Soc. 2004, 126, 9938-9939) was followed.

[0089] First, the amino group of dopamine was protected as the tert-butyloxycarbonyl (BOC) derivative (11) through reaction with di-tert-butyldicarbonate [(BOC)O] in the presence of NaOH / dioxane. Compound 11 was then treated with excess benzyl bromide / KCO to give the di-O-benzyl ether 12. The amino group of 12 was released by hydrolysis of the BOC-carbamate with trifluoroacetic acid to produce the desired di-O-benzylated derivative 13.

[0090] Scheme VII [ka]

[0091] To introduce a linker at 13, reaction of this compound with succinic anhydride successfully afforded the amide-acid 14. However, coupling reactions between 14 and D5 in the presence of EDCI / HOBt, as well as with other coupling reagents, were unsuccessful (see Scheme VIII below).

[0092] Scheme VIII [ka]

[0093] Fortunately, coupling of 14 with D5 via mixed anhydride 15 (not isolated) produced the doxycycline-dopamine conjugate 16 (see Scheme IX), which was more easily isolated and purified. Hydrogenolytic removal of the benzyl group of D16 led to the target molecule, i.e., the preferred compound of the present invention, Pegasus. The product was isolated by precipitation and purified by reverse-phase HPLC using methanol:water 30:70 as the solvent. The chromatogram recorded in methanol exhibited a single peak with a retention time of 8.4 min.

[0094] Scheme IX [ka]

[0095] Example 2 - The most reliable synthetic route for the compound Pegasus General Experimental Procedures NMR spectra were obtained at 500 MHz ( 1 H) or 125.7MHz ( 13 C) or 300MHz ( 1 H) or 75.6MHz ( 13 C). Chemical shifts (δ, in ppm) were recorded relative to an internal standard ( 1 In the case of H, Me4Si (δ: 0.0) in CDCl3 and 13References are made to CDCl3 (δ: 77.0) for C or to the residual solvent peak. Data multiplicities are indicated as s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broad); coupling constants (J) are given in Hertz (Hz). 1 H and 13 C NMR spectral assignments in 2D 1 H-COSY or NOESY, and 2D 1 H- 13 C HSQC was used for analysis. High-resolution mass spectra (HRMS) were obtained using electrospray ionization (ESI) and Q-TOF detection. Analytical thin-layer chromatography (TLC) was performed on silica gel 60 F254 aluminum-backed plates (0.2 mm layer thickness) and silica gel 60 RP F254S aluminum-backed plates. Spots were visualized by exposure to UV light and by charring with Ce / Mo stain. Column chromatography was performed on silica gel 60 (230-400 mesh) or, for reversed phase, octadecyl-functionalized silica gel as the stationary phase. The chromatographic solvent or stepwise solvent polarity gradient used is specified for each individual compound. Optical rotations were measured at room temperature in a 1 dm cell at the sodium D line in the indicated solvent. Unless otherwise noted, all commercially available compounds were used as obtained from the supplier without further purification.

[0096] Doxycycline free form (D1) from doxycycline hydrochloride [ka]

[0097] Doxycycline hydrochloride (2.0 g, [α] D 20=-113.5 (c1, 10 mM HCl in MeOH) was dissolved in distilled water (6 mL) and 1 M aqueous NaOH was added dropwise until pH ≈ 5, at which point a white solid formed. The solid was filtered and dissolved in methanol (20 mL). The solution was stirred for 20 min until a new white precipitate appeared. The solid was filtered and dried to provide doxycycline free form (D1, 1.3 g, 75%); [α] D 20 =+250.7(c 1,THF), 1 H NMR((CD3)2CO,500MHz)δ:7.53(t,1H,J 7,8 =J 8,9 =8.1Hz,H-8),7.02(d,1H,J 8,9 =8.1Hz,H-9),6.82(d,1H,J 7,8 =8.1Hz,H-7),4.21(brt,1H,J 5a,5 ≒J 4a,5 ≒4.0Hz,H-5), 3.59(brd,1H,J 4a,4 =9.6Hz,H-4),2.93(dq,1H,J 6,Me =6.7,J 5a,6 =12.8Hz,H-6),2.74(dd,1H,J 5a,5 =4.0,J 5a,6 =12.8Hz,H-5a),2.63(dd,1H,J 4a,4 =9.6,J 4a,5 =4.0Hz,H-4a),2.53(s,6 H,N(CH3)2),1.61(d,3H,J 6,Me =6.7Hz,CH3); 13 C NMR((CD3)2CO,125.7MHz)δ:194.7(C-1,3,11),174.9,174.5(C-12,CONH2),163.4(C-10),148.7(C-6a),137.6(C-8),117.4,116.8,116.4(C- 7,9,10a),106.4(C-11a),92.0(C-2),76.0(C-12a),69.9(C-5),66.2(C -4),48.9(C-4a),48.2(C-5a),42.6(N(CH3)2),38.5(C-6),16.7(CH3).

[0098] Applying this same procedure to doxycycline hyclate produced 69% pure D1.

[0099] Synthesis of Doxycycline Methyl Iodide (D2) [ka]

[0100] To a solution of D1 (2.0 g, 4.5 mmol) in dry THF (40 mL) was added dropwise methyl iodide (2.5 mL, 40 mmol) at room temperature under an Ar atmosphere. The reaction was stirred at 45 °C for 24 h, and the solvent was removed by evaporation under reduced pressure. The resulting solid was washed with anhydrous CHCl (15 mL) and dried to give D2 (2.6 g, 98%). [α] D 20 +31.2(c 1.0,THF); 1 H NMR((CD3)2CO,200MHz)δ:7.55(t,1H,J 7,8 =J 8,9 =8.0Hz,H-8),6.97(d,1H,J 8,9 ≒8.0Hz,H-7), 6.86(d,1H,J 7,8 ≒8.1Hz,H-9),5.44(s,1H,OH),3.89(brt,1H,H-5),3.69(s,9H,N(CH3)3),3.53(brd,1H,H-4),2.97-2.60(m,3H,H-4a,5a,6),1.56(d,3H,J 6,Me = 6.4 Hz, CH3); HRMS (ESI) m / z [M] + Calculation C 23 H 27 N2O5459.1762, actual measurement 459.1762.

[0101] Synthesis of 4-dedimethylaminodoxycycline D3 [ka]

[0102] To a solution of D2 (1 g, 1.7 mmol) in 50% (v / v) aqueous acetic acid (30 ml), zinc dust (0.6 g, 9.2 mmol) was added, and the mixture was stirred at room temperature for 20 min. The suspension was filtered through a pad of Celite. The filtrate was diluted with water (100 mL) containing concentrated HCl (1 mL), and the mixture was stirred in an ice bath for 1 h. The solid that formed was filtered and dried in vacuo. The amorphous solid was characterized as D3 (0.48 g, 70%); [α] D 20 -50.8(c 1.0, acetone); 1 H NMR((CD3)2CO,500MHz)δ:7.51(t,1H,J 7,8 =J 8,9 =8.0Hz,H-8),6.96(d,1H,J 8,9 =8.0Hz,H-9),6.84(d,1H,J 7,8 =8.0Hz,H-7),4.41(d,1H,J 5,OH =8.5Hz,OH), 3.79(br q,1H,J 4a,5 =9.5,J 5a,5 =7.7,J 5,OH =8.5Hz,H-5),3.06(dd,1H,J 4a,4 =5.5,J 4,4' =18.6Hz,H-4),2.97(dd,1H,J 4a,4' =2.9,J 4,4' =18.6Hz,H-4'),2.79(m,1H,J 6,Me =6.8,J 5a,6 =12.5Hz,H-6),2.51(dd,1H,J 5a,5 =7.7,J 5a,6 =12.5Hz,H-5a),2.47(ddd,1H,J 4a,4 =5.5,J 4a,4' =2.9,J 4a,5 =9.5Hz,H-4a),1.57(d,3H,J 6,Me =6.8Hz,CH3); 13C NMR((CD3)2CO,125.7MHz)δ:195.9,194.6,193.2(C-1,3,11),176.0,174.9(C-12,CONH2),163.1(C-10),149.1(C-6a),137.4(C-8),116.8,116.7, 116.6(C-7,9,10a),107.4(C-11a),99.7(C-2),75.7(C-12a),69.6(C-5) ,44.4(C-4a),47.6(C-5a),39.5(C-6),30.6(C-4),16.4(CH3);HRMS(ESI) m / z [M+Na] + Calculation C 20 H 19 NNaO8424.0998, actual measurement 424.1003.

[0103] Synthesis of 4-dedimethylamino-9-nitrodoxycycline D4 [ka]

[0104] To D3 (0.5 g, 1.2 mmol) was slowly added 97% H2SO4 (4 mL), which had previously been cooled in an ice bath. To this solution was added KNO3 (0.16 g, 1.6 mmol), and the mixture was stirred at 0 °C for 2 h. The reaction was diluted with cold methanol (5 mL), and a precipitate formed upon the addition of water (35 mL). The brown solid was filtered and dried in vacuo, then dissolved in acetone (4 mL). A black precipitate appeared upon the addition of dichloromethane (15 mL). The mixture was treated with activated charcoal with stirring for 20 min, then filtered through a Celite pad. The solid was discarded, and the filtrate was slowly diluted with hexane (70 mL), inducing the precipitation of D4 (0.35 g, 65%) as a yellow solid; [α] D 20 -6.5(c 1.0, acetone); 1 H NMR((CD3)2CO,200MHz)δ:8.15(d,1H,J 7,8 =8.6Hz,H-8),7.17(d,1H,J 7,8 =8.6Hz,H-7),3.83(dd,1H,J 4a,5=11.4,J 5a,5 =7.8Hz, H-5), 3.00-2.91 (m, 3H, H-4, H-4' and H-6), 2.61 (dd, 1H, J 5a,6 =12.5,J 5a,5 =7.8Hz,H-5a),2.47(ddd,1H,J 4a,4 =5.3,J 4a,4' =3.3,J 4a,5 =11.4Hz,H-4a),1.60(d,3H,J 6,Me =6.8Hz,CH3); 13 C NMR((CD3)2CO,50.3MHz)δ:165.5(C-12,CONH2),155.1(C-7),137.4(C-6a),132.1(C-9),118.5,118.2(C-9,10a) HRMS(ESI) m / z [M+Na] + Calculation C 20 H 18 N2NaO 10 469.0854, actual measurement 469.0854.

[0105] Synthesis of 9-amino-4-dedimethylaminodoxycycline D5 [ka]

[0106] To a solution of D4 (0.2 g, 0.5 mmol) in methanol (6 mL) containing 0.1% concentrated HCl, 10% Pd / C (30 mg) was added, and the mixture was treated with hydrogen at 44 psi at room temperature for 20 h. The mixture was filtered through a Celite pad, and the residue was washed with methanol. The filtrate and washing liquors were pooled and concentrated. The resulting residue was dissolved in ethanol (2 mL), and ethyl acetate (30 mL) was added dropwise to induce precipitation, affording D5 (125 mg, 60%) as a slightly gray solid; [α] D20 -30.0 (c 0.5, MeOH); 1 H NMR(CD3OD,500MHz)δ:7.61(d,1H,J 7,8 =8.3Hz,H-8),7.10(d,1H,J 7,8 =8.3Hz,H-7),3.67(dd,1H,J 4a,5 =10.8,J 5a,5 =8.0Hz,H-5),3.05(dd,1H,J 4a,4 =5.5,J 4,4' =18.6Hz,H-4),2.92(dd,1H,J 4a,4' =2.4,J 4,4' =18.6Hz,H-4'),2.78(m,1H,J 6,Me =6.9,J 5a,6 =12.4Hz,H-6),2.44(dd,1H,J 5a,5 =8.0,J 5a,6 =12.4Hz,H-5a),2.32(ddd,1H,J 4a,4 =5.5,J 4a,4' =2.4,J 4a,5 =10.8Hz,H-4a),1.55(d,3H,J 6,Me =6.9Hz, CH3); 13 C NMR(CD3OD,125.7MHz)δ:196.5,194.5 x 2(C-1,3,11),177.2,175.04(CONH2,C-12),155.8(C-10),150.4(C-6a),130.9(C-8),118.9,118.1(C-9,10a) 117.3(C-7),108.0(C-11a),99.5(C-2),76.0(C-12a),69.8(C-5),47.7(C-5a),44.9(C-4a),40.0(C-6),31.3(C-4),16.2(CH3);HRMS(ESI) m / z [M] + Calculate C 20 H 21 N2O8417.1292; test 417.1295.

[0107] 9-(2-クロロアセトアミド)-4-デジメチルアミノドキシサイクリンD6の synthesis

change

[0108] In a brown-bottom flask, D5 (125 mg, 0.30 mmol) was dissolved in anhydrous DMF (1.5 mL), and chloroacetyl chloride (25 μL, 0.3 mmol) and NaHCO (73 mg, 0.90 mmol) were added. The mixture was stirred at room temperature for 30 min, and then additional amounts of chloroacetyl chloride (19 μL, 0.2 mmol) and NaHCO (36 mg, 0.40 mmol) were added. The mixture was stirred at room temperature for 2 h, and the reaction was terminated by evaporation of DMF. Addition of methanol to the residue led to the formation of a black precipitate, which was filtered and discarded. Addition of water to the methanol solution led to the formation of a brown solid, which was dried and identified as D6 (54 mg, 36%); 1 H NMR((CD3)2SO,200MHz);8.13(d,1H,J 7,8 =8.2Hz,H-8),6.92(d,1H,J 7,8 =8.3Hz,H-7),4.41(s,2H,CH2Cl),3.45(m,1H,H-5),2.95(m,2H,H-4,H-4'),2.50-2.43(m,2H,H-4a,5, overlaps with DMSO),1.42(d,3H,J 6,Me =6.3Hz,CH3).

[0109] Synthesis of pentacyclic derivative D7 [ka]

[0110] In a round-bottom flask equipped with a magnetic bar, D6 (24 mg, 0.03 mmol) was dissolved in anhydrous CHCN (0.7 mL). Dopamine (0.03 mmol) was then added, and the reaction was purged with nitrogen and stirred at 50 °C for 15 h. Evaporation of the solvent led to a fairly complex mixture of products according to silica gel TLC (EtOAc:C5H5N:H2O 9:2.5:1). Precipitation from water led to a small amount of solid (7 mg), enriched in the product identified as D7. The contaminant was unreacted D6. Diagnostic signal for D7:1 H NMR((CD3)2CO,200MHz);8.45(d,1H,J 7,8 =8.5Hz,H-8),6.96(d,1H,J 7,8 =8.5Hz,H-7),4.67(d,1H,J=5.2Hz,COCH2O),4.60(d,1H,J=5.2Hz,COCH2O),3.45(m,1H,H-5),1.52(d,3H,J 6,Me = 6.9 Hz, CH3). The singlet observed at 4.67 ppm suggested the formation of a cyclic product with chloride displacement by intramolecular nucleophilic attack on the halocarbon of HO-phenol.

[0111] Synthesis of 9-(5-bromopentanamide)-D5(D8) and attempted reaction with dopamine [ka]

[0112] To a solution of 5-bromovaleric acid (325 mg, 1.8 mmol) in anhydrous dichloromethane (9 mL) cooled to 0 °C was added dropwise a solution of DCC (185 mg, 0.9 mmol) in anhydrous dichloromethane (1.8 mL). The reaction was stirred at 0 °C for 30 min, then cooled to -18 °C (ice / salt bath) and stirred for 1 h. After this time, the urea by-product precipitate was filtered and discarded. Concentration of the organic solution provided the symmetric anhydride from 5-bromovaleric acid, which was saved for the next step.

[0113] In a separate round-bottom flask, D5 (100 mg, 0.24 mmol) was dissolved in dry DMF (3.0 mL) and stirred at room temperature while a DMF solution of 5-bromovaleric anhydride was added. Upon addition of sodium bicarbonate (0.04 g, 0.5 mmol), the reaction mixture was stirred for 3 h. Examination by reverse-phase TLC (HO:MeOH 1:1) showed the formation of a new spot with an Rf of 0.31. The mixture was filtered to remove excess NaHCO and acidified to pH 2 with concentrated aqueous HCl. The solvent was removed by evaporation, and the residue was dissolved in MeOH. The addition of water induced the precipitation of D8 (90 mg, 50%).

[0114] 1 H NMR(CDCl3,300MHz);8.53(d,1H,J 7,8 =8.5Hz,H-8),6.89(d,1H,J 7,8 =8.5Hz,H-7),3.77(m,1H,H-5),3.45(m,3H,CH2Br),1.60(d,3H,J 6,Me = 5.3 Hz, CH3); product 13 C NMR ((CD3)2CO, 125.7 MHz) showed signals of valeramide residues at 34.4, 33.0, 24.9, and 24.2 ppm. HRMS(ESI) m / z [M+Na] + Calculation C 25 H 28 N2BrO9579.0973, measured 579.0971 and 581.0941 (isotopic pattern 1:1).

[0115] As with compound D6, and under similar conditions, attempted substitution of the bromide of D8 with dopamine was unsuccessful.

[0116] Synthesis of D9 by addition of D5 with succinic anhydride and attempted coupling of D9 with dopamine [ka]

[0117] A solution of D5 (0.2 g, 0.5 mmol) in dry DMF (2 mL) was stirred at room temperature while succinic anhydride (81 mg, 1.0 mmol) and sodium bicarbonate (0.08 g, 1.0 mmol) were added sequentially. The reaction was stirred for 2 h, and then examination by reverse-phase TLC (H2O:MeCN 7:3) showed the formation of a new spot at Rf 0.34. The crude mixture was filtered to remove excess NaHCO3 and acidified to pH 2 with concentrated HCl. The solvent was removed by evaporation. Purification by reverse-phase column chromatography (H2O:MeCN 7:3) provided D9 (150 mg, 60%); 1 H NMR((CD3)2CO,500MHz);8.46(d,1H,J 7,8 =8.3Hz,H-8),6.90(d,1H,J 7,8 =8.3Hz,H-7),3.79(t,1H,J 4a,5 =J 5a,5 =10.2Hz,H-5),3.05(dd,1H,J 4a,4 =5.5,J 4,4' =18.7Hz,H-4),2.96(dd,1H,J 4a,4' =3.2,J 4,4' =18.7Hz,H-4'),2.81(t,2H,J x,z =6.6Hz,HZ),2.70(t,2H,J x,z = 6.6Hz, HX), 2.70 (H-6, overlapping under HX), 2.50-2.43 (m, 2H, H-4a, 5), 1.54 (d, 3H, J 6,Me =6.8Hz,CH3); 13C NMR((CD3)2CO,125.7MHz)δ:;195.9,194.6,193.1(C-1,3,11),176.3,174.9,174.2,171.3(CONH2,COOH,C-12,CONH),152.1(C-10), 142.6(C-6a),127.3,127.2(C-8,9),116.0,115.8(C-7,10a),107.4(C-11a),99.7(C-2) ,75.7(C-12a),69.6(C-5),47.8(C-5a),44.3(C-4a),39.1(C-6),32.2(C-4),16.3(CH3). The CX and CZ signals are below the NMR solvent signal (peal).

[0118] The coupling reaction between D9 and dopamine hydrochloride was unsuccessful in the presence of EDCI / HOBt as coupling reagents. The following procedure was employed for the coupling reaction: D9 (1 eq) was dissolved in dry DMF (2 mL), and EDCI (1 eq.) and HOBt (1 eq.) were added to the solution, which was stirred at 0 °C for 30 min. The solution was stirred at room temperature for another 1.5 h. TEA (3 eq.) and dopamine hydrochloride were then added to the reaction mixture. The solution was monitored by reverse-phase TLC, but no change was observed, even when the solution was left stirring overnight at room temperature.

[0119] Synthesis of D10 by coupling of dopamine with succinic anhydride [ka]

[0120] In a brown round-bottom flask equipped with a septum, dopamine hydrochloride (0.2 g, 1.0 mmol) was dissolved in pyridine (3 mL) and succinic anhydride (140 mg, 1.4 mmol) was slowly added. The mixture was stirred for 24 h, and then TLC (EtOAc:MeOH 9:1) showed complete conversion of dopamine (Rf 0) to a faster-migrating product (Rf 0.27). The solvent was evaporated under reduced pressure, and the residue was treated with MeOH to give D10 (1.22 g, 91%) as a white amorphous solid. 1 H NMR((CD3)2CO,500MHz)δ:6.72(d,1H,J 5,6 =8.0Hz,H-6),6.71(d,1H,J 3,5 =2.0Hz,H-3),6.53(dd,1H,J 3,5 =2.0,J 5,6 =8.0Hz,H-5),3.35(t,2H,J 1',2' =6.7Hz,H-2'),2.64(t,2H,J 1',2' =6.7Hz,H-1'),2.59(t,1H,J 1'',2'' =7.0Hz,H-1''),2.47(t,1H,J 1'',2'' =7.0Hz,H-2''); 13 C NMR(CDCl3,125.7MHz)δ:174.1,172.6(CO),145.5,144.1(C-1,2),131.7(C-4),120.6(C-5),116.4,115.8(C-3,6),41.8(C-2'),35.6(C-1'),31.0× 2(C-1'',2'').

[0121] Coupling of dopamine derivative (D10) with D5 using DCC or EDCI as coupling agents was attempted but was unsuccessful. The general procedure for the coupling reaction was as follows: Equimolar amounts (0.07 mmol) of D10 and D5 in dry DMF (1 mL) were stirred under an argon atmosphere for 30 min. Then, the coupling agent (2 eq.) was added to the mixture at room temperature. The reaction was stirred for 12 h. TLC analysis (nBuOH:EtOH:HO 0.5:0.5:0.1) showed that D5 (Rf 0.20) and D10 (Rf 0.66) remained unreacted, so formation of the expected product was not observed.

[0122] Synthesis of N-tert-butyloxycarbonyl-2-(3,4-dihydroxyphenyl)ethanamine (N-Boc dopamine, 11) [ka]

[0123] In a brown round-bottom flask, dopamine hydrochloride (1.0 g, 5.3 mmol) was dissolved in a previously sonicated mixture of dioxane (10 mL) and 1 M aqueous NaOH (5 mL). The mixture was stirred for 10 min, and di-tert-butyl dicarbonate (1.3 g, 5.8 mmol) was added. The reaction was stirred at room temperature for 4 h under a N2 atmosphere, and then TLC (hexane:EtOAc 2:8 with 1 drop of AcOH) showed complete conversion of dopamine (Rf 0) to a faster-moving product (Rf 0.8). The solution was acidified to pH 2 with HCl (1 M) and then extracted with EtOAc (x 3). The organic layer was dried (Na2SO4) and concentrated to provide 11 (1.22 g, 91%). 1 H NMR((CD3)2CO,500MHz)δ:7.69(brs,2H,OH),6.73(d,1H,J 5,6= 8.0Hz,H-5),6.70(d,1H,J 2,6 =2.0Hz,H-2),6.53(dd,1H,J 2,6= 2.0,J 5,6= 8.0Hz,H-6),5.87(brs,1H,NH),3.20(dt,2H,J = 6.1Hz,H-1'),2.62(t,2H,J =6.1Hz,H-2'),1.39(s,9H,(CH3)3CON); 13 C NMR(CDCl3,125.7MHz)δ:156.6(CO),145.8,144.2(C-3,4),132.1(C-1),120.8(C-6),116.6 ,116.0(C-2,5),78.4((CH3)3CON),43.1(C-1'),36.3(C-2'),28.6((CH3)3CON);HRMS(ESI) m / z [M+Na] + Calculation C 13 H 19 NNaO4276.1206; Actual measurement 276.1204.

[0124] The methylene signal adjacent to N(H-1') was seen as two partially overlapping triplets due to the rapid interconversion of two rotamers resulting from tert-butyl carbamate.

[0125] Synthesis of N-tert-butyloxycarbonyl-2-(3,4-bis(benzyloxy)phenyl)ethanamine (di-O-benzyl-N-Boc dopamine, 12) [ka]

[0126] A suspension of 11 (1.3 g, 5.3 mmol) dissolved in DMF (20 mL) and K2CO3 (4.4 g, 32 mmol) was stirred at room temperature for 30 min. Upon cooling to 0 °C (ice bath), benzyl bromide (1.8 mL, 16 mmol) was added dropwise with continued stirring. The reaction was kept for 24 h, and then monitored by TLC (hexane:EtOAC 7:3) showed the conversion of the starting compound (Rf = 0.35) to a less polar spot (Rf = 0.57). Addition of water and cooling to 0 °C led to the formation of a solid product. The mixture was kept in an ice bath with stirring for 1 h to complete the precipitation. The solid was filtered, washed with water, and dried to give 12 (1.65 g, 72%); 1 H NMR(CDCl3,300MHz)δ:7.48-7.27(m,10 H,H-aromatic),6.87(d,1H,J5,6= 8.1Hz,H-5),6.80(d,1H,J 2,6= 2.0Hz,H-2),6.70(dd,1H,J 5,6= 8.1,J 2,6= 2.0Hz, H-6), 5.14, 5.13 (2s, 2H, OCH2Ph), 4.49 (brs, 1H, NH), 3.31 (dt, 2H, J 1',2'= 6.7Hz,H-1'),2.69(t,2H,J 1',2'= 6.7Hz,H-2'),1.44(s,9H,(CH3)3)C); 13 C NMR(CDCl3,75MHz)δ:155.9(NHCO),149.0,147.7(C-3,4),137.5,137.3,132.4,128.5,127.8,127.4,127.3,121. 7,115.9,115.5(C-1,2,5,6),71.5,71.4(OCH2Ph),41.8(C-1'),35.7(C-2'),28.4((CH3)3)C),27.7((CH3)3)C). HRMS(ESI) m / z [M+Na] + Calculation C 27 H 31 NNaO4456.2153; measured 456.2145.

[0127] For 11, the methylene signal adjacent to N(H-1') was seen as two partially overlapping triplets due to the rapid interconversion of two rotamers resulting from the tert-butyl carbamate.

[0128] Synthesis of 2-(3,4-bis(benzyloxy)phenyl)ethanamine (13) [ka]

[0129] To a solution of 12 (0.84 g, 1.94 mmol) in CHCl (11 mL), trifluoroacetic acid (1.7 mL) was added and stirred at room temperature for 2 h. The reaction was monitored by TLC (hexane:EtOAc 3:7), which revealed the conversion of the starting material (Rf 0.57) to a polar product (Rf 0). The pH of the solution was adjusted to 9 by the addition of 1 M NaOH and quickly extracted with CHCl (20 mL). The organic layer was washed with saturated aqueous NaCl, dried, and concentrated to provide 13 (0.46 g, 72%). 1 H NMR(CDCl3,300MHz)δ:7.52-7.25(m,10 H,H-aromatic),6.90(d,1H,J 5,6= 8.1Hz,H-5),6.81(d,1H,J 2,6= 1.9Hz,H-2),6.71(dd,1H,J 5,6= 8.1,J 2,6= 1.9Hz, H-6), 5.17, 5.15 (2s, 2H, OCH2Ph), 2.87 (t, 2H, J 1',2'= 6.7Hz,H-1'),2.64(t,2H,J 1',2'= 6.7Hz,H-2'),1.81(brs,2H,NH2); 13 C NMR(CDCl3,75MHz)δ:149.0,147.6(C-3,4),137.5,137.4,128.5,127.8,127.4(C-aromatic Ph),133.2(C- 1),121.8(C-6),116.1(C-2),115.4(C-5),71.5,71.4(OCH2Ph),43.4(C-1'),39.3(C-1');HRMS(ESI) m / z [M] + Calculation C 22 H 24 NO2334.1802, actual measurement 334.1804.

[0130] Synthesis of 14 by addition of 13 to succinic anhydride and attempted coupling of 14 with D5 [ka]

[0131] To a solution of 13 (115 mg, 0.3 mmol) in DMF (3 mL), K2CO3 (140 mg, 1.0 mmol) was added, and the solution was stirred for 10 min. Upon addition of succinic anhydride (40 mg, 0.4 mmol), the solution was stirred at room temperature for 4 h. Examination by TLC (EtOAc, with 2 drops of HAcO) indicated complete formation of the faster-moving compound (Rf 0.25). The reaction mixture was acidified to pH 2 with 1 M HCl (≈0.5 mL), and water was added to induce precipitation. The mixture was stirred in an ice bath for 1 h, and the formed solid was filtered. The solid was purified by column chromatography (hexane:EtOAc 5:5 to 3:7, with 1% HAcO) to provide 14 (127 mg, 84%); 1 H NMR(CDCl3,200MHz)δ:7.49-7.22(m,10 H,H-aromatic),6.88(d,1H,J 5,6= 8.1Hz,H-5),6.76(brd,1H,J 2,6= 2.1Hz,H-2),6.66(dd,1H,J 5,6= 8.1,J 2,6= 2.1Hz,H-6),5.76(t,J NH , c= 5.9Hz, NH), 5.15, 5.14 (2s, 2H, OCH2Ph), 3.44 (q, 2H, J 1',2'= J 1',NH= 6.5Hz,H-1'),2.66(m,4H,H-2',b),2.36(t,2H,J a,b= 6.4Hz,Ha); 1 H NMR((CD3)2SO,500MHz)δ:7.49-7.29(m,10 H,H-aromatic),7.90(brs,1H,-NH),6.96(d,1H,J 5,6= 8.2Hz,H-5),6.94(d,1H,J 2,6= 1.9Hz,H-2),6.71(dd,1H,J 5,6= 8.2,J 2,6= 1.9Hz, H-6), 5.11, 5.08 (2s, 2H, OCH2Ph), 3.20 (dd, 2H, J 1',2'= 7.5,J 1',NH= 5.6Hz,H-1'),2.60(d,2H,J c,d=7.5Hz,H-2'),2.41(d,2H,J a,b= 6.7Hz,Ha), 2.29(d,2H,J a,b= 6.7Hz,Hb); 13 C NMR((CD3)2SO,125.7MHz)δ:173.9(COOH),170.9(CONH),148.2,146.7(C-3,4),132.7(C-1),128.4 127.7 × 2,127.6,127.5,(OCH2Ph) 121.1(C-6),115.1(C-2),114.7(C-5),70.2,70.1(OCH2Ph),40.4(C-1'),34.7(C-2'),30.1(Cb),29.2(Ca) HRMS(ESI) m / z [M] + Calculation C 26 H 28 NO5434.1962, actual measurement 434.1952.

[0132] Coupling reactions between 14 and D5 in the presence of EDCI / HOBt as well as with other coupling reagents were attempted but were unsuccessful.

[0133] Doxycycline-dopamine [N 1 -(4-dedimethylaminodoxycycline-9-yl)-N 4 Synthesis of -(3,4-dihydroxyphenethyl)succinamide, D16 [ka]

[0134] A solution of 14 (156 mg, 0.36 mmol) in anhydrous DMF (2 mL) was cooled to −5 °C, and ethyl chloroformate (33 μL, 0.36 mmol) and triethylamine (50 μL, 0.36 mmol) were added dropwise over 15 min. The intermediate anhydrous carbonate 15 was not isolated. After an additional 15 min, D5 (100 mg, 0.24 mmol) and finely powdered NaHCO (20 mg, 0.24 mmol) in dry DMF (2 mL) were added sequentially. The reaction was stirred for 2 h, and then silica gel TLC (EtOAc:CHN:HO 9:2.5:1) showed the formation of a slightly faster-migrating spot (Rf 0.70) compared to D5 (Rf 0.68). In contrast to D5, which was only apparent at 254 nm under UV irradiation, the product was apparent at λ 254 and 365 nm. The reaction was also monitored using reverse-phase TLC (HO:MeCN 1:1), which confirmed the formation of a new spot (Rf 0.35) that migrated slower than D5 (Rf 0.75). The crude mixture was filtered to remove excess NaHCO3 and acidified to pH 2 with HCl (c). The solvent was removed by evaporation under reduced pressure, and the oily residue was washed with a 5% aqueous solution of LiCl to remove excess DMF.

[0135] Purification by reverse-phase column chromatography (MeOH:HO 1:1 → 3:2) followed by evaporation of the solvent provided D16 as a yellowish powder (200 mg, 60%). D 20 -30.1(c 0.2,MeOH); 1 H NMR(CD3OD,500MHz);δ:8.16(d,1H,J 7,8 =8.3Hz,H-8),7.47-7.22(m,10H,aromatic),6.90(d,1H,J f,j =1.0Hz,Hf),6.88(d,1H,J i,j =8.2Hz,Hi), 6.80(d,1H,J 7,8 =8.3Hz,H-7),6.72(d,1H,J f,i =7.9,J i,j =1.0Hz,Hj),5.12-5.00(m,6H,CH2Ar),3.60(q,1H,J4a,5 =10.7,J 5a,5 =8.0Hz,H-5),3.35(t,2H,J=7.2Hz,CH2-c),3.03(brd,1H,J 4,4' =18.0Hz,H-4),2.90(brd,1H,J 4,4' =18.0Hz,H-4'),2.69(t,2H,J=7.3Hz,CH2-d),2.56(m,1H,J=6.7Hz,H-6),2.51,2.42(2 t,4H,J=6.8Hz,CH2-a,CH2-b),2.35-2.28(m,2H,H-4a,5a),1.43(d,3H,J 6,Me =6.7Hz, CH3); 13 C NMR(CD3OD,125.7MHz)δ:196.4,195.4,194.6(C-1,3,11),175.0,174.6,174.2,173.2(CONH2,2 CONH,C-12),153.5(C-10),150.3,148.7(Cg,Ch),144.2(C-6a),134.3(Ce),138.8-128.8( Ph-based C-aromatic C-8),126.7(C-9),122.9(Cj),117.1,117.0(Cf,Ci),116.6(C-10a),116.1(C -7),108.0(C-11a),100.1(C-2),72.6,72.4(C-12a,CH2Ar),69.9(C-5),48.0,44.9(C-4a,5 a),42.0(Cc),39.6(C-6),36.0(Cd),32.0,31.4(Ca,Cb),30.2(C-4),16.2(CH3);HRMS(ESI) m / z [M+Na] + Calculate C 46 H 46 N3O 12 832.3076, tested 832.3078.

[0136] Hydrogenation decomposition of D16: Synthesis of Pegasus A solution of compound D16 in MeOH (5 mL) containing 10% Pd / C (50 mg) was hydrogenated at 44 psi (3 atm) for 20 h. The mixture was diluted with methanol (10 mL), and the catalyst was filtered through a pad of Celite and washed with methanol (4 mL). The filtrate and washings were collected and concentrated. The residue was dissolved in a minimum amount of methanol and precipitation was induced upon addition of water. The resulting brown-yellow solid was isolated by centrifugation and dried to provide Pegasus (85 mg, 54%); [α] D 20 -16.7(c 1.1,MeOH); 1 H NMR(CD3OD,500MHz);δ:8.16(d,1H,J 7,8 =7.9Hz,H-8),6.87(d,1H,J 7,8 =7.9Hz,H-7),6.67(d,1H,J i,j =7.9Hz,Hi),6.64(s,1H,Hf),6.52(d,1H,J j,i =7.9Hz,Hj),3.63(q,1H,J 4a,5 =10.2,J 5a,5 =8.3Hz, H-5), 3.35 (m, 2H, overlap with MeOD, CH2-c), 3.15 (brd, 1H, J 4,4' =17.7Hz,H-4),2.92(dd,1H,J 4,4' =17.7Hz,H-4'),2.74,2.55(brt,2H,CH2-a,CH2-b),2.63(t,2H,J=6.5Hz,CH2-d),2.63(1H,overlapping under CH2-d,H-6),2.34(m,2H,H-4a,5a),1.50(d,3H,J 6,Me =6.4Hz,CH3); 13C NMR(CD3OD,125.7MHz)δ:196.4-195.5(C-1,3,11),175.1,175.0,174.5,173.3(CONH2,2 CONH,C-12),153.6(C-10),146.2,144.7(Cg,Ch),144.4(C-6a),132.1(Ce),129.3 (C-8),126.6(Cg),121.1(Cj),116.8,116.3(Cf,Ci),116.7(C-10a),116.1(C-7), 108.0(C-11a),100.0(C-2),76.1(C-12a),69.9(C-5),48.1,44.9(C-4a,5a),42.4 (Cc),39.7,35.9(C-6,Cd),33.1,32.3(Ca,Cb),31.3(C-4),16.2(CH3);HRMS(ESI) m / z [M+Na] + Calculation C 32 H 33 N3NaO 12 674.1956, actual measurement 674.1972.

[0137] Example 3 - Characterization of the ability of compounds of the invention to interfere with toxic AS aggregation To evaluate the effect of Pegasus (D9) on AS amyloid fibril formation, aggregation reactions were performed according to LeVine (LeVine H, 3rd. Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution. Protein Sci 1993; 2(3): 404-10; LeVine H, 3rd. Quantification of beta-sheet amyloid fibril structures with thioflavin T. Methods Enzymol 1999; 309: 274-84.). Briefly, the formation of cross-β structures was followed by adding thioflavin T (ThT), a fluorescent cross-β reporter probe, to aliquots extracted from the incubation mixture at different times.

[0138] Expression and purification of recombinant human AS was performed as previously described (Hoyer W, Antony T, Cherny D, Heim G, Jovin TM, Subramaniam V. Dependence of AS aggregate morphology on solution conditions. J Mol Biol 2002; 322(2): 383-93), and purity was assessed by SDS-PAGE. Stock solutions of monomeric AS were prepared in 20 mM HEPES (pH 7.4). Prior to measurement, protein solutions were filtered and centrifuged at 12,000 x g for 30 min. Protein concentrations were determined using an extinction coefficient ε = 5600 cm. -1 M -1was determined by absorbance at 275 nm using The aggregation protocol used was based on previous studies (Kaylor J, Bodner N, Edridge S, Yamin G, Hong DP, Fink AL. Characterization of oligomeric intermediates in alpha-synuclein fibrillation: FRET studies of Y125W / Y133F / Y136F alpha-synuclein. J Mol Biol 2005; 353(2): 357-72; Danzer KM, Haasen D, Karow AR, et al. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007; 27(34): 9220-32; Avila CL, Torres-Bugeau CM, Barbosa LR, et al. Structural characterization of heparin-induced glyceraldehyde-3-phosphate dehydrogenase protofibrils preventing alpha-synuclein oligomeric species toxicity. J Biol Chem 2014; 289(20): 13838-50; Gonzalez-Lizarraga F, Socias SB, Avila CL, et al. Repurposing doxycycline for synucleinopathies: remodeling of alpha-synuclein oligomers towards non-toxic parallel beta-sheet structured species. Scientific reports 2017; 7: 41755).

[0139] For the aggregation reaction, aliquots of monomeric AS (70 μM) in 20 mM HEPES (pH 7.4) were incubated in a Thermomixer comfort (Eppendorf) at 37°C and 600 rpm in the absence or presence of 10 or 50 μM D9. Aggregation was monitored on a Horiba FluoroMax-4 spectrofluorometer using the ThT fluorescence assay. As observed in Figure 2, D9 was able to inhibit AS aggregation (at both 10 μM and 50 μM) just as potently as the positive control doxycycline (Figure 2).

[0140] Example 4 - Determination of antibiotic activity of compounds of the invention To test the antibiotic activity of the compounds synthesized in Example 1, an assay was carried out using E. coli DH5α (Gram(-)) as a sensitive indicator strain. We used serial two-fold dilutions to determine the minimum inhibitory concentration (MIC) in solid LB medium, with a starting concentration of 2 mg / ml and a volume of 10 μl at each dilution.

[0141] The antibacterial activity of test compounds was evaluated using the disk diffusion method (Kavanagh, F. Dilution methods of antibiotic assays in Analytical Microbiology. 1963; Pomares MF, Vincent PA, Farias RN, Salomon RA. Protective action of ppGpp in microcin J25-sensitive strains. J Bacteriol. 2008 - 190:4328-34). Briefly, filter-paper disks were impregnated with 10 μl of two-fold serial dilutions of test compounds and placed on LB solid medium Petri dishes. Then, aliquots (50 μl) of stationary-phase E. coli DH5α cultures were mixed with 3 ml of top agar (0.7% agar) and plated. After overnight incubation at 37°C, the plates were examined for various degrees of inhibition. The degree of inhibition produced by the test compound is expressed as the minimum inhibitory concentration (MIC), which is defined as the lowest concentration of compound that inhibits visible bacterial growth. Each test was performed in duplicate against the reference compound doxycycline. As seen in Table 1, the reference compound doxycycline exhibited an MIC of 31.25 μg / ml, while the compound of the present invention, D9, exhibited no antibiotic activity at the concentrations tested.

[0142] [Table 1] Table 1: Antibiotic activity of Pegasus (D9) and other related compounds determined by disc diffusion assay.

[0143] Example 5 - Cytotoxicity of Compounds of the Invention 5.1. Effect of Pegasus cytotoxicity on neuroblastoma SH-SY5Y cells The effect of Pegasus (D9) on cell viability was studied in the SH-SY5Y neuroblastoma cell line using a colorimetric Thiazolyl Blue Tetrazolium Blue (MTT) metabolic activity assay, which reports the number of viable cells based on mitochondrial activity (Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65(1-2): 55-63).

[0144] SH-SY5Y cells were seeded at 15,000 cells / well in 100 μl of DMEM supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic / antimycotic in 96-well plates and incubated at 37°C and 5% CO2 for 24 h. Cells were then treated with 25 μl aliquots of 5 μM, 50 μM, or 100 μM D9 solution (final concentrations in the well were 1 μM, 10 μM, and 20 μM, respectively) and incubated for 24 h. To determine cell viability, an MTT assay was used as previously described by Mosmann (1983). All experiments were performed in triplicate, and relative cell viability (%) was expressed as a percentage compared to the untreated control condition.

[0145] No significant difference was observed in MTT turnover between cells treated with Pegasus up to 20 μM and control-treated cells, indicating that Pegasus (at 1, 10, and 20 μM) did not have any cytotoxic effect on SH-SY5Y cells (Figure 3).

[0146] 5.2. Effect of Pegasus cytotoxicity on the microglial Bv2 cell line We also investigated the ability of D9 to induce cytotoxicity in Bv2 cells, a microglial cell line derived from the C57 / BL6 mouse model, using an MTT assay. To do so, Bv2 cells were incubated at 37°C in the presence or absence of various Pegasus concentrations. Bv2 cells retain the morphological and functional characteristics of microglia and are therefore a broad microglial model. These cells were immortalized with a v-raf / v-myc-carrying J2 retrovirus and express the nuclear v-myc and cytoplasmic v-raf oncogene products, as well as the env gp70 antigen at the surface level.

[0147] Bv2 cells were seeded at 15,000 cells / well in 100 μl of DMEM supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic / antimycotic (PSA) in poly-L-lysine-treated 96-well plates and incubated at 37°C and 5% CO2 for 24 h. Cells were then treated with 25 μl aliquots of 50 μM and 100 μM Pegasus solutions (final concentrations in the well: 10 μM and 20 μM) and incubated for 24 h. To determine cell viability, a colorimetric MTT metabolic activity assay was used as previously described by Mosmann. All experiments were performed in triplicate, and relative cell viability (%) was expressed as a percentage compared to the untreated control condition. Results indicated that Pegasus did not induce cytotoxicity at concentrations up to 20 μM, as no significant changes in the MTT signal were observed (Figure 4).

[0148] Example 6 - Pegasus is a novel AS gene in SH-SY5Y cells. f Reduces the levels of intracellular reactive oxygen species induced by Among the pathophysiological mechanisms implicated as key pathways of neurodegeneration, mitochondrial dysfunction and oxidative stress have been shown to enhance neuroinflammation and protein misfolding. These processes, in turn, trigger mitochondrial dysfunction and oxidative stress, driving a vicious cycle that can be fatal to cells, especially neurons. Consequently, AS aggregates can induce increased production of reactive oxygen species (ROS), thereby exacerbating the neurodegenerative process.

[0149] To characterize the antioxidant properties of D9, we assessed its protective effect against AS-induced production of reactive oxygen species (ROS) in a cellular model. For this purpose, SH-SY5Y cells were cultured in a cellular model containing AS fibrils (AS f ) (AS incubated at 37°C and 600 rpm for 120 h), and the reactive oxygen species produced were examined using CellROX® Orange Reagent (Invitrogen), which forms stable fluorescent compounds upon oxidation by ROS.

[0150] As shown in Figure 5, SH-SY5Y cells were either left untreated (non-treated, NT) or treated with 7 μM AS f (AS f ), 7 μM AS f +D9 10μM(AS f +D9), and D9 10 μM alone as a control (D9). In addition, cells were also treated with doxycycline 10 μM + 7 μM AS as a positive control. f (AS fCells were also treated with 10 μM doxycycline (+Doxy), and 10 μM doxycycline alone (Doxy). All conditions were incubated for 24 h at 37°C and 5% CO2. After treatment and incubation, intracellular reactive oxygen species were revealed by analysis with fluorescence microscopy using 5 μM CellROX® Orange Reagent (Invitrogen) and adding the probe for 30 min and washing three times with PBS. Fluorescence images of randomly selected fields were acquired using a Zeiss Axio Vert.A1 inverted fluorescence microscope with identical acquisition parameters.

[0151] As expected, SH-SY5Y cells showed a higher cellular uptake of AS, as indicated by the stronger emission of the fluorescent probe CellROX® Orange Reagent (Fig. 5a, b). f' Conversely, cells exhibited increased amounts of intracellular ROS when treated with AS in the presence of D9. f When treated with AS (Fig. 5c), no increase in ROS production was observed. f These results indicate that D9 was able to protect SH-SY5Y cells from oxidative stress specifically induced by D9. Similarly, the positive control doxycycline was also able to protect cells from oxidative stress (Figure 5e). In addition, neither the presence of D9 nor doxycycline induced intracellular ROS (Figures 5d, f). Quantification of the results obtained by microscopy is shown in Figure 5g.

[0152] Example 7 - Effect of compounds of the present invention on the release of the pro-inflammatory cytokine IL-1β Interleukin-1β (IL-1β) is a potent pro-inflammatory cytokine that is crucial for host-defense responses to infection and injury, and is the best characterized and best studied of the 11 IL-1 family members.

[0153] To evaluate the effect of Pegasus on LPS-activated microglia, Bv2 cells were pretreated with Pegasus (D9) (200 μM). After 4 h of treatment, cells were stimulated with LPS (10 μg / mL, final concentration) for 24 h. Doxycycline (Doxy) (200 μM) and dexamethasone (Dexa) (200 μM) were used as positive controls for anti-inflammatory effects. IL-1β cytokine concentrations were measured by ELISA assay (Mouse IL-1 beta ELISA Kit, Cat# BMS6002, Invitrogen) according to the manufacturer's instructions.

[0154] Pegasus significantly reduced the inflammatory effects of LPS, leading to reduced production of IL-1β. In addition, treatment of Bv2 cells with Pegasus(D9) alone did not significantly increase IL-1β release, indicating that this molecule does not exert a pro-inflammatory effect in Bv2 cells (Figure 6).

[0155] Example 8 - Effect of Pegasus on apoptosis in a recombinant cytochrome-C-GFP HEK293T cell line model Identification of genes associated with familial forms of PD has uncovered many molecular pathways involved in neurodegeneration. One such gene is PTEN-induced kinase 1 (PINK1), a mitochondrial serine / threonine-protein kinase that protects cells from stress-induced mitochondrial dysfunction. PINK1 mutations have been shown to be associated with sporadic PD patients. PINK1 is the second most common causative gene in early-onset PD, and mutations in this gene cause the autosomal recessive form of the disease. Frequent missense or truncating mutations in PINK1 are implicated in the pathogenesis of PARK6 (familial PD type 6). Overexpression of wild-type PINK1 has been shown to prevent mitochondrial release of apoptogenic cytochrome c, activation of caspase-3, and apoptotic cell death induced by the proteasome inhibitor MG132. N-terminally truncated PINK1 (NΔ35), which lacks the mitochondrial localization sequence, does not block MG132-induced cytochrome C release and cytotoxicity. Thus, the release of cytochrome C from damaged mitochondria is considered a central event in apoptotic signaling. To characterize the ability of Pegasus (D9) to induce mitochondrial damage and apoptosis, as assayed by cytochrome C release from mitochondria, we used a recombinant cytochrome C-tGFP HEK293 cell line (INNOPROT # P30801) (Goldstein JC, Munioz-Pinedo C, Ricci JE, et al. Cytochrome C is released in a single step during apoptosis. Cell Death Differ 2005; 12(5): 453-62).

[0156] The effect of Pegasus on mitochondrial cytochrome C-tGFP localization and distribution was investigated in the HEK293 / cytochrome C-tGFP cell line (INNOPROT # After 24 h incubation with 200 μM D9 in 100 μg / ml (P30801), cells were visualized by confocal microscopy. Images were acquired on a ZEISS LSM800 Confocal Microscope.

[0157] As shown in Figure 7, no differences in the localization and distribution of the apoptotic marker cytochrome C-tGFP were observed between control and Pegasus-treated conditions after 24 h of incubation in the presence or absence of 200 μM Pegasus (D9). Cytochrome C appeared to be localized to mitochondrial structures in both cases (Figure 7, inset).

[0158] Example 9 – Effect of Pegasus on lysosomes in the neuroblastoma cell line SH-SY5Y Lysosomes are the final destination of the autophagic pathway. LysoTracker™ fluorescent probes are dyes that preferentially accumulate in vesicles at acidic pH and can be used to study organelle localization, their resident proteins, assess organelle functionality, quantify lysosome number and vesicular pH abnormalities (Eskelinen EL, Schmidt CK, Neu S, et al. Disturbed cholesterol traffic but normal proteolytic function in LAMP-1 / LAMP-2 double-deficient fibroblasts. Mol Biol Cell 2004; 15(7): 3132-45), and to examine the efficiency of autophagosome / lysosome fusion in living cells (Gonzalez-Polo RA, Boya P, Pauleau AL, et al. The apoptosis / autophagy paradox: autophagic vacuolization before apoptotic death. J Cell Sci 2005; 118(Pt 14): 3091-102.), which is widely used to track lysosomes in live and fixed cells.

[0159] The effect of Pegasus on lysosomal activity in SH-SY5Y cells was estimated by visualizing the localization and number of lysosomes marked by LysoTracker™ Deep Red (ThermoFisher #L12492) after 24 h treatment with 200 μM Pegasus. After incubation, cells were fixed in PFA 4% and prepared for confocal microscopy. Images were acquired on a ZEISS LSM800 confocal microscope.

[0160] The results suggest that the compound does not interfere with lysosomal biogenesis in SH-SY5Y cells, as no obvious differences were observed in SH-SY5Y cells incubated with or without 200 μM Pegasus (Figure 8).

[0161] Example 10 - D1 and D2 receptor binding efficiency of compounds of the present invention Dopamine receptors belong to the superfamily of G protein-coupled seven-transmembrane proteins. G protein-coupled receptors are a component of one of the major signal transduction pathways in eukaryotic cells. The sequences encoding these receptors are highly conserved across mammalian species in those regions thought to contribute to the agonist-antagonist binding site. Various members of the dopamine receptor family are generally classified as either "D1-like" or "D2-like." D1-like receptors include D1 and D5 receptors, which activate adenylate cyclase via coupling to GS proteins.

[0162] The assay was performed by Innoprot SL, Spain, to evaluate the D1 and D2 receptor activation efficiency of Pegasus, the intermediate compound DOXI-5, and dopamine as a reference compound, both freshly obtained by the donor and sent together with the test compound, taking into account any effects that may be caused by the travel conditions of the samples.

[0163] Test Compound - Pegasus(D9) - DOXI-5 (D5) - Test dopamine (Sigma-Aldrich, Pegasus and reference compound sent together with DOXI-5) - New dopamine (Sigma-Aldrich, reference compound obtained at the assay site)

[0164] Reagents and equipment - DMEM (Dulbecco's Modified Eagle's Medium, Sigma-Aldrich, D6429) - DMEM-F12 (Sigma-Aldrich, D9785) - Opti-MEM (Opti-Minimal Essential Medium, Thermo-Fisher scientific 31985070, batch 1932076) - FBS (Fetal Bovine Serum, Sigma-Aldrich F7524, batch BCBW6329) - Flat-bottom black 96-well plates (Becton Dickinson 353219, batch E1804340)

[0165] method HEK_ cAMP Nmd_FP650_D1 and U2OS_ cAMP Nmd_FP650_D2 cells were seeded in 96-well plates at densities of 30,000 and 20,000 cells / well, respectively, and maintained in DMEM or DMEM-F12 medium supplemented with 10% FBS at 37°C in a humidified 5% CO atmosphere for 24 h. On day 2, cells were treated with ten 1:3 serial dilutions starting at 30 μM of fresh dopamine, test dopamine, Pegasus (D9), or DOXI-5 (D5) compounds diluted in Opti-MEM. Cells were then incubated for 24 h. All experiments were performed in triplicate.

[0166] To detect activation of the Nomad biosensor, the assay medium was removed and replaced with 100 ml of DPBS with calcium and magnesium. cAMP The agonist effect of the compounds was assessed in the Nmd_FP650_D1 cell line using a Sinergy II Biotek microplate reader with appropriate filters for the FP650 protein fluorescence signal (excitation / emission max=590 / 665 nm). cAMP Measured by quantifying the change in fluorescence emission of the Nomad biosensor. cAMP Images of Nmd_FP650_D2 cells were acquired using the CellInsight CX7 HCS Platform, and the number of fluorescent vesicles per cell was quantified using HCS Studio Cell Analysis Software.

[0167] result The effect of compounds on modulating D1 or D2 receptor activation was analyzed by measuring cAMP signaling using a Nomad biosensor-based assay. For agonist assays, cells were incubated with fresh dopamine, test dopamine, Pegasus (D9), or DOXI-5 (D5) at 10 different concentrations (1:3 serial dilutions starting from 30 μM) dissolved in Opti-MEM for 24 hours.

[0168] The effect of the compounds was analyzed in HEK_cAMPNmd_FP650_D1 by measuring changes in fluorescence intensity using a Synergy II Biotek microplate reader (FIG. 9).

[0169] The result is 5.48x10 new dopamine -7 Similarly, the test dopamine showed an EC50 of 6.92 x 10 -7 In the case of Pegasus, the potency of compounds activating D1 receptors was reduced by an order of magnitude to 2.8 x 10 -6Finally, DOXI-5 (D5) did not act as an agonist of the D1 receptor, as it did not cause activation of the Nomad biosensor.

[0170] This same experiment was also performed in the U2OS_cAMPNmd_FP650_D2 cell line (FIG. 10). The effects of the compounds were analyzed by quantifying the number of fluorescent vesicles in the cytoplasm of the cells using HCS Studio Cell Analysis Software.

[0171] In this case, the new dopamine was administered at a dose below the EC50 of the test dopamine (7.2x10 -6 M) as well as 7.44x10 -6 The EC50 of M was 1.13x10 -5 While DOXI-5 (D5) showed an EC50 of M, it did not act as a D2 receptor agonist, as it did not cause activation of the Nomad biosensor.

[0172] conclusion - Compounds Pegasus (D9) and DOXI-5 (D5) have very similar effects in both D1 and D2 functional assays. - Travel conditions did not significantly affect dopamine's ability to act as an agonist for D1 and D2. - Pegasus (D9) exhibits agonist potential at both D1 and D2 receptors, but to a somewhat lesser extent than dopamine. DOXI-5 (D5) is not an agonist of D1 or D2 receptors, as it does not induce activation of the Nomad biosensor.

Claims

1. A compound defined by the following formula: 【Chemistry 1】

2. 10. A pharmaceutical composition comprising a compound of claim 1 and one or more pharmaceutically acceptable excipients.

3. The pharmaceutical composition of claim 2 for use in the treatment of a neurodegenerative disease.

4. The pharmaceutical composition described in claim 3, wherein the neurodegenerative disease is a synucleinopathy.

5. The pharmaceutical composition described in claim 4, wherein the neurodegenerative disease is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA), neuroaxonal dystrophy, and Alzheimer's disease with Lewy bodies confined to the amygdala (AD / ALB).

6. The pharmaceutical composition described in claim 5, wherein the neurodegenerative disease is PD.

7. The pharmaceutical composition of claim 3, wherein the neurodegenerative disease is selected from the group consisting of standard Alzheimer's disease (AD), Huntington's disease, amyotrophic lateral sclerosis, brain tumors, and infectious diseases of the brain.

8. The following steps a) Removal of the dimethylamino group at the C-4 position of doxycycline b) introducing an amino group at the C-9 position of the doxycycline deaminated in step a); c) selectively protecting the phenolic hydroxyl group of dopamine as a benzyl ether d) introducing a linker into the amino group of the product of step c) by reaction with succinic anhydride to give the corresponding amide acid. e) coupling the acid group of the amic acid with the amino group of doxycycline via a mixed anhydride to obtain a doxycycline-dopamine conjugate; and f) deprotecting the benzyl group of the doxycycline-dopamine conjugate obtained in step e); A method for preparing the compound of claim 1, comprising:

Images